Show simple item record

dc.contributor.authorElkord, Eyad
dc.contributor.authorAlcantar-Orozco, E M
dc.contributor.authorDovedi, S J
dc.contributor.authorTran, D Q
dc.contributor.authorHawkins, Robert E
dc.contributor.authorGilham, David E
dc.date.accessioned2010-11-17T15:39:31Z
dc.date.available2010-11-17T15:39:31Z
dc.date.issued2010-11
dc.identifier.citationT regulatory cells in cancer: recent advances and therapeutic potential. 2010, 10 (11):1573-86 Expert Opin Biol Theren
dc.identifier.issn1744-7682
dc.identifier.pmid20955112
dc.identifier.doi10.1517/14712598.2010.529126
dc.identifier.urihttp://hdl.handle.net/10541/115720
dc.description.abstractIMPORTANCE OF THE FIELD: The active suppression of immune responses against tumor is a major barrier to the likely success of cancer immunotherapy. There is now compelling evidence implicating T regulatory cells (Tregs) as being key players driving immune suppression. Elevated frequencies of Tregs within the peripheral circulation and tumor microenvironment of cancer patients correlate with poor prognosis and reduced survival. Understanding the mechanism of Treg elevation is critical for the development of new approaches aiming to modulate the frequency and function of Tregs to enhance the efficacy of cancer immune-based therapies. AREAS COVERED IN THIS REVIEW: This review focuses on current knowledge concerning Tregs in cancer and discusses putative mechanisms which underlie the expansion of Tregs in cancer patients. Additionally, we review current strategies to deplete/suppress Treg activity, the limitations of these strategies and future perspective for improving their efficacy. WHAT THE READER WILL GAIN: An insight of the current aspects concerning Treg subsets in cancer and an overview of recent advances in the identification of Treg-specific markers, in addition to the potential strategies to target Tregs for enhancing antitumor immunity. TAKE HOME MESSAGE: Mechanisms by which Treg functions modulate the immune response to tumors are becoming further understood. However, specific markers to tumor-specific/induced Tregs are yet to be clearly identified, which is a major limitation in optimizing strategies to specifically target Tregs in cancer. Despite this, strategies aimed at modulating Tregs in patients are providing some early encouraging results supporting the overall concept and indicating that further studies are clearly warranted.
dc.language.isoenen
dc.subjectCanceren
dc.subjectT Regulatory Cellsen
dc.subjectImmunotherapyen
dc.subjectTherapeutic Strategiesen
dc.subjectTreg Markersen
dc.titleT regulatory cells in cancer: recent advances and therapeutic potential.en
dc.typeArticleen
dc.contributor.departmentUniversity of Salford, School of Environment and Life Sciences, Centre for Biochemistry, Drug Design and Cancer Research, Salford, UK. e.elkord@salford.ac.uken
dc.identifier.journalExpert Opinion on Biological Therapyen
html.description.abstractIMPORTANCE OF THE FIELD: The active suppression of immune responses against tumor is a major barrier to the likely success of cancer immunotherapy. There is now compelling evidence implicating T regulatory cells (Tregs) as being key players driving immune suppression. Elevated frequencies of Tregs within the peripheral circulation and tumor microenvironment of cancer patients correlate with poor prognosis and reduced survival. Understanding the mechanism of Treg elevation is critical for the development of new approaches aiming to modulate the frequency and function of Tregs to enhance the efficacy of cancer immune-based therapies. AREAS COVERED IN THIS REVIEW: This review focuses on current knowledge concerning Tregs in cancer and discusses putative mechanisms which underlie the expansion of Tregs in cancer patients. Additionally, we review current strategies to deplete/suppress Treg activity, the limitations of these strategies and future perspective for improving their efficacy. WHAT THE READER WILL GAIN: An insight of the current aspects concerning Treg subsets in cancer and an overview of recent advances in the identification of Treg-specific markers, in addition to the potential strategies to target Tregs for enhancing antitumor immunity. TAKE HOME MESSAGE: Mechanisms by which Treg functions modulate the immune response to tumors are becoming further understood. However, specific markers to tumor-specific/induced Tregs are yet to be clearly identified, which is a major limitation in optimizing strategies to specifically target Tregs in cancer. Despite this, strategies aimed at modulating Tregs in patients are providing some early encouraging results supporting the overall concept and indicating that further studies are clearly warranted.


This item appears in the following Collection(s)

Show simple item record